ReviewCell biology international2020
New insights into small-cell lung cancer development and therapy.
Review in Cell biology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients.Clinical and experimental medicine · 2023Pooled it
- Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial.Signal transduction and targeted therapy · 2024Trial
- Efficacy and safety of radiotherapy following chemoimmunotherapy in extensive-stage small cell lung cancer: a retrospective comparative cohort study of consolidation versus salvage indications.Journal of thoracic disease · 2026Article
- RNA-binding protein RALYL-mediated BCL11B RNA stability promotes immune escape in small cell lung cancer through transcriptional activation of BUB3.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Ubiquitin-Specific Protease 45 Inhibits Lung Adenocarcinoma Ferroptosis by Regulating Ubiquitination and Stability of Glutathione Peroxidase 4.Cancer medicine · 2026Article
- Segmentectomy or Lobectomy in T1N0M0 Non-Small Cell Lung Carcinomas: The Prognostic Role of Histology and Vascular Invasion.Updates in surgery · 2026Article
- Failure patterns and the influence of the TNM staging systems on prognosis in limited disease small cell lung Cancer (SCLC): the Turkish Oncology Group (TOG) study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- ALDH1L2 induces resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis.Redox biology · 2026Article
- Are iris masses in lung carcinoma always a metastasis: Two case reports.World journal of methodology · 2026Article
- Impact of timing of adjuvant chemotherapy on survival for early-stage node-negative small-cell lung cancer.JTCVS open · 2026Article
- Generation of a human vascularized 3D airway model replicating native mucosal heterogeneity.Frontiers in bioengineering and biotechnology · 2026Article
- Application and prospects of lung organ-on-a-chip in the development of new drugs.Biomedical engineering online · 2025Review
- Small cell lung cancer: relationship with HLA-I alleles and gene mutation.Journal of cardiothoracic surgery · 2025Article
- Effectiveness of Atezolizumab in Addition to Chemotherapy in ES-SCLC: A Retrospective Real-World Monocentric Study.Cancers · 2025Article
- Diagnostic value and therapeutic efficacy of serum levels of pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) in patients with lung cancer.Journal of medical biochemistry · 2025Article
- Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer.Medical sciences (Basel, Switzerland) · 2025Review
- Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.Current treatment options in oncology · 2025Review
- Chelerythrine Inhibits TGF-β-Induced Epithelial-Mesenchymal Transition in A549 Cells via RRM2.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Associations between four insulin resistance (IR) surrogates and the risk of small cell lung cancer (SCLC).Scientific reports · 2025Article
- The effects and toxicity profiles of consolidative and salvage thoracic radiotherapy following chemoimmunotherapy in patients with extensive-stage small cell lung cancer.Journal of biomedical research · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first-line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.